Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | OXTR | P30559 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23882697 | 1.00 | MAPT (0.34) | MAPTLMNACYP17A1OXTRCYP3A4 | |
| SCHEMBL26159475 | 1.00 | MAPT (0.34) | MAPTLMNACYP17A1OXTRCYP3A4 | |
| SCHEMBL30251075 | 1.00 | MAPT (0.34) | MAPTLMNACYP17A1OXTRCYP3A4 | |
| SCHEMBL30251047 | 1.00 | MAPT (0.34) | MAPTLMNACYP17A1OXTRCYP3A4 | |
| SCHEMBL30251209 | 1.00 | MAPT (0.34) | MAPTLMNACYP17A1OXTRCYP3A4 | |
| SCHEMBL23906135 | 0.90 | CYP19A1 (0.36) | MAPTLMNACYP17A1CYP11B1CYP11B2 | |
| SCHEMBL30250884 | 0.90 | CYP19A1 (0.36) | MAPTLMNACYP17A1CYP11B1CYP11B2 | |
| SCHEMBL23882791 | 0.90 | CYP19A1 (0.36) | MAPTLMNACYP17A1CYP11B1CYP11B2 | |
| SCHEMBL30251309 | 0.90 | CYP19A1 (0.36) | MAPTLMNACYP17A1CYP11B1CYP11B2 | |
| SCHEMBL30251285 | 0.90 | CYP19A1 (0.36) | MAPTLMNACYP17A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| WO-2021198283-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | HLA-DRB1, CD74, HLA-C | MAPT 882/4885LMNA 3720/4885CYP17A1 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.